ORLANDO, FLORIDA / ACCESS Newswire / October 31, 2025 / RedChip Companies will air interviews with 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) and NDT Pharmaceuticals Inc. (OTC:NDTP) on the RedChip ...
The FDA warning letters mostly went to cosmetic websites. In each case, the FDA said the companies were offering unofficial ...
Third Quarter 2025 Financial Results: Total revenue for the quarter ended September 30, 2025 was $134.2 million, up 12% from $119.8 million in the same period of 2024. This growth and operational ...
The first botulinum toxin product, onabotulinumtoxinA, was approved by the FDA in 1989. Since then, FDA has approved several ...
It is fair to say (no matter what else can be said) that the current administration is outcome- rather than process-driven. This general ...
The Food and Drug Administration has issued 18 warning letters to online retailers selling unapproved and misbranded Botox ...
The head of the U.S. Food and Drug Administration’s drug division, Dr. George F. Tidmarsh, resigned on November 2, 2025, one ...
CollaBraid is the first product the company aims to bring to market in 2026. The technology is a hybrid collagen suture — a thread-like material that surgeons use to stitch tissue together — for a ...
Ironically enough, his initial downfall had nothing to do with Daraprim. Soon after he became infamous, federal prosecutors ...
Ionis Pharmaceuticals, Inc. shows promise with new drug launches and a robust pipeline. Click here to read IONS stock ...
Alvotech, for its part, has run into repeated issues with the FDA at its Icelandic drug plant. Since the company’s biosimilar accord with Teva began, problems at the Reykjavik facility have led to two ...
The FDA has announced new rules for the approval of biosimilar drug products that could reduce 5- to 8-year timelines by half.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback